Results 111 to 120 of about 12,210 (151)
<i>In Silico</i> Design and Analysis of a Novel Ranibizumab-derived Peptide against the Vascular Endothelial Growth Factor. [PDF]
J Ophthalmic Vis ResAfarid M +4 more
europepmc +1 more source
U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. [PDF]
PLoS OneMalhotra K +4 more
europepmc +1 more source
Long-term disease control with anti-VEGF treat-and-extend treatment in macular edema due to retinal vein occlusion. [PDF]
BMC OphthalmolFischer S, Hoffmann L, Hatz K.
europepmc +1 more source
Endophthalmitis Caused by α-Streptococcal Following Intravitreal Ranibizumab Biosimilar Administration Using a Prefilled Syringe. [PDF]
CureusUtsunomiya K +4 more
europepmc +1 more source
Anti-VEGF versus laser therapy for retinopathy of prematurity: a systematic review and meta-analysis focusing on recurrence patterns and retreatment needs. [PDF]
Int J Retina VitreousKrungkraipetch L +2 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2007
Ranibizumab is the antigen-binding fragment of a recombinant, humanised monoclonal antibody, which binds with high affinity to, and inhibits the activity of, all active forms of vascular endothelial growth factor A, an important mediator in the development of choroidal neovascularisation.
Stephanie K A, Blick +2 more
openaire +3 more sources
Ranibizumab is the antigen-binding fragment of a recombinant, humanised monoclonal antibody, which binds with high affinity to, and inhibits the activity of, all active forms of vascular endothelial growth factor A, an important mediator in the development of choroidal neovascularisation.
Stephanie K A, Blick +2 more
openaire +3 more sources